Home/Pipeline/EIR-0205

EIR-0205

Stargardt Disease

PreclinicalActive

Key Facts

Indication

Stargardt Disease

Phase

Preclinical

Status

Active

Company

EIR Biopharma

About EIR Biopharma

EIR Biopharma, founded in 2019 and based in San Diego, is pioneering a novel therapeutic approach centered on modulating the Ephrin receptor, a key regulator of cellular guidance, survival, and angiogenesis. Its lead asset, EIR-1003, is a small molecule antagonist in preclinical development for glaucoma and other ocular diseases, with a secondary program, EIR-0205, for Stargardt disease. The company leverages partnerships with top academic institutions and is led by a team with extensive biopharma experience, aiming to build a pipeline-in-a-mechanism platform that extends beyond ophthalmology into major disease areas with high unmet need.

View full company profile

Therapeutic Areas

Oncology Immunology Ophthalmology Neurodegenerative Diseases

Other Stargardt Disease Drugs

Drug	Company	Phase	Status
KIO-301	Kiora Pharmaceuticals	Preclinical	Active
Emixustat HCl	Kubota Vision	Phase 3	Active
Gildeuretinol (ALK-001)	Alkeus Pharmaceuticals	Phase 3	Active
MCO-010	Nanoscope Therapeutics	Phase 2	Active
SB-007	SpliceBio	Phase 1/2	Active
LBS-008	Lin BioScience	Phase 3	Active
OCU410ST	Ocugen	Phase 2/3	Active
ABO-504	Abeona Therapeutics	Preclinical	Active